Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report

被引:0
|
作者
Fujishiro, Takeshi [1 ]
Mashiko, Taro [1 ]
Masuoka, Yosihito [1 ]
Yamada, Misuzu [1 ]
Furukawa, Daisuke [1 ]
Yazawa, Naoki [1 ]
Kawashima, Yohei [2 ]
Ogawa, Masami [2 ]
Hirabayashi, Kenichi [3 ]
Nakagohri, Toshio [1 ]
机构
[1] Tokai Univ, Sch Med, Dept Surg, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
[2] Tokai Univ, Dept Gastroenterol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
[3] Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
来源
SURGICAL CASE REPORTS | 2018年 / 4卷
关键词
Locally advanced pancreatic cancer; Carbon ion radiotherapy; Gemcitabine plus nab paclitaxel; Conversion surgery;
D O I
10.1186/s40792-018-0522-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Pancreatic cancer has a very high mortality rate worldwide, and about 30-40% of all patients have extensive vascular involvement at initial diagnosis that precludes surgical intervention. Here, we describe our experience in a patient with locally advanced pancreatic cancer (LAPC) who underwent R0 conversion surgery after undergoing a combination of chemotherapy and carbon-ion radiotherapy (CIRT), which led to long-term relapse-free survival (23 months). Case presentation: A 41-year-old woman presented a month ago with epigastralgia referred to our facility and was subsequently diagnosed with pancreatic cancer cStage III (Ph, TS2 (35 mm), cT4, cCH1, cDU1, cS1, cRP1, cPL1, cVsm0, cAsm1, cN0, cM0) that was also categorized as an unresectable LAPC. She immediately underwent 3 cycles of induction chemotherapy (gemcitabine + nanoparticle albumin-bound (nab-) paclitaxel) followed by CIRT with concurrent gemcitabine. Although significant shrinkage of the primary tumor occurred, frequent cholangitis due to duodenal stenosis of unknown etiology prevented continued chemotherapy, and 9 months after the first visit, she underwent a radical, subtotal, stomach-preserving, pancreaticoduodenectomy (SSPPD). Histopathologic examination of the resected tissue revealed a R0 resection with a histological response of Evans grade IIB. She was administered an almost full dose of S-1 as adjuvant chemotherapy for 6 months and has shown no signs of recurrence in 23 months. Conclusions: We report a first case of successful conversion surgery for an initially unresectable LAPC after rapid induction GEM + nab-PTX chemotherapy followed by CIRT. Rapid induction GEM + nab-PTX chemotherapy followed by CIRT for LAPC might be a safe and effective treatment option.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report
    Takeshi Fujishiro
    Taro Mashiko
    Yosihito Masuoka
    Misuzu Yamada
    Daisuke Furukawa
    Naoki Yazawa
    Yohei Kawashima
    Masami Ogawa
    Kenichi Hirabayashi
    Toshio Nakagohri
    [J]. Surgical Case Reports, 4 (1)
  • [2] Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report
    Watanabe, Yusuke
    Tatsuguchi, Takaaki
    Date, Kenjiro
    Shinkawa, Tomohiko
    Kuga, Hirotaka
    Tamiya, Sadafumi
    Nishihara, Kazuyoshi
    Nakano, Toru
    [J]. JOURNAL OF MEDICAL CASE REPORTS, 2024, 18 (01)
  • [3] Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report
    Yusuke Watanabe
    Takaaki Tatsuguchi
    Kenjiro Date
    Tomohiko Shinkawa
    Hirotaka Kuga
    Sadafumi Tamiya
    Kazuyoshi Nishihara
    Toru Nakano
    [J]. Journal of Medical Case Reports, 18
  • [4] Radical Carbon-Ion Radiotherapy for Locally Advanced Unresectable Pancreatic Cancer
    Nakata, K.
    Ohtsuka, T.
    Mori, Y.
    Miyasaka, Y.
    Makoto, S.
    Nagai, E.
    Nakamura, M.
    [J]. PANCREAS, 2016, 45 (10) : 1528 - 1529
  • [5] A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer
    Shinoto, Makoto
    Terashima, Kotaro
    Suefuji, Hiroaki
    Matsunobu, Akira
    Toyama, Shingo
    Fukunishi, Kaori
    Shioyama, Yoshiyuki
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 129 (02) : 333 - 339
  • [6] Long-term outcome after combined carbon-ion radiotherapy and chemotherapy for locally advanced pancreatic cancer
    Shinoto, Makoto
    Hirata, Hidenari
    Suefuji, Hiroaki
    Toyama, Shingo
    Ueda, Minoru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Carbon-Ion Radiotherapy Combined with Concurrent Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Case Series Analysis
    Okamoto, Masahiko
    Shiba, Shintaro
    Kobayashi, Daijiro
    Miyasaka, Yuhei
    Okazaki, Shohei
    Shibuya, Kei
    Ohno, Tatsuya
    [J]. CANCERS, 2023, 15 (10)
  • [8] Local effect and gastrointestinal toxicity for carbon-ion radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Shinoto, Makoto
    Shioyama, Yoshiyuki
    Suefuji, Hiroaki
    Matsunobu, Akira
    Toyama, Shingo
    Kudo, Sho
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience
    Su, Yungyeh
    Ting, Yulin
    Wang, Chihjung
    Chao, Yingjui
    Liao, Tingkai
    Su, Pingjui
    Chiang, Naijung
    Liao, Ichuang
    Yu, Yuting
    Liu, Yisheng
    Tsai, Hongming
    Li, Yijie
    Huang, Chienjui
    Liu, Iting
    Tsai, Huijen
    Yen, Chiajui
    Shan, Yanshen
    Chen, Litzong
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (05): : 2189 - 2202
  • [10] A single institutional experience of carbon-ion radiotherapy for locally advanced pancreatic cancer.
    Shinoto, Makoto
    Shioyama, Yoshiyuki
    Suefuji, Hiroaki
    Toyama, Shinto
    Matsumoto, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)